EN DE
Watch Imugene Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Imugene Ltd (IMU) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Imugene Ltd stock A$0.03, price A$0.03, upside +0.0%, quality 21 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU000000IMU9

IL Imugene Ltd logo Thin data Nov 17, 2026

Imugene Ltd

IMU · AU

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value A$0.0330 · Fairly valued 
Moderate moat 56/100 · thin data
Revenue last quarter 60% below a year ago. 
Quality 21/100 
Falling price (downtrend) 
Weak Growth (revenue 5y +1.2 %/yr in AUD) 
Negative free cash flow 
Trails peers (2/8) 
Thin data 
Estimate
Watch Imugene Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$20.57 A$0.0300 Fair Value A$0.0330 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range A$0.0300 – A$20.57 · fair‑value band A$0.0305 – A$0.0356 · the A$0.0330 price screens below the A$0.0330 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Imugene in your weekly email

Every Wednesday you see whether Imugene is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.

Show moreShow less

Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study.

The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer.

Imugene Limited is headquartered in Sydney, Australia.

Stock analysis

Imugene Ltd (IMU) currently trades at A$0.0330, while our estimate is A$0.0330, so the stock looks roughly fairly valued today (gap 0.0%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.0305 (bear) to A$0.0356 (bull), the price of A$0.0330 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Imugene Ltd reported revenue of A$4.4M in FY2025 versus A$7.2M in FY2021, a compound −11.7%/yr. Reported net income was −A$105M in FY2026.

Key figures

Market cap A$18.3M (≈ $12.3M) Micro · P/S ratio 10.1 · EPS (TTM) A$−0.3200 · Return on equity −314% · Return on assets (EBIT) −113% (5-year average) · Operating margin −5,246% · Revenue (TTM) A$2.1M · Revenue growth (YoY) −59.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (low confidence).

What moves the price

The share trades about 92% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 0%, IMU screens cheaper than that median.

Fair Value

Bear A$0.0305 Fair Value A$0.0330 Bull A$0.0356
Price A$0.0330 · Upside +0.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 21/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 36
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−11.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−30.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.2%
Start year 2020 (pandemic). Over 10 years: +21.3% a year
Revenue growth 30 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−261.4% (2020) → −1,613.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch IMU, get fair value alerts →

Compare Imugene Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 21 · Bottom 25%
Fair Value upside +0.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −59.8% · Bottom 25%
Balance sheet
Debt / equity 0.29× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.03× · Cheaper than median
P/S (12 months) 8.77× · Pricier than median
PEG 4.07× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 0
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)86 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs IMU
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs IMU
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs IMU
argenx SE ARGX $950.95 $908.40 −4% vs IMU
CSL Limited CSL A$199.55 A$186.49 −7% vs IMU
Moderna, Inc MRNA $215.27 $135.64 −37% vs IMU
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs IMU
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs IMU
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs IMU
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs IMU

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Imugene Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Imugene Ltd Fair Value". https://www.fairvalue-calculator.com/stock/IMU

Frequently asked questions

Is Imugene Ltd (IMU) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is A$0.0330 versus a price of A$0.0330, about +0% upside (fairly valued).
What is the fair value of IMU?
Our estimate for Imugene Ltd is A$0.0330 (as of Nov 17, 2026), built from audited fundamentals. The current price: A$0.0330.
What is the quality score of IMU?
Imugene Ltd has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Imugene Ltd (IMU)?
Our calculated price target is the estimate of A$0.0330 (as of Nov 17, 2026). Cautious scenario A$0.0305, optimistic scenario A$0.0356. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Imugene Ltd stock forecast for 2026?
Our estimate puts fair value at A$0.0330, about +0% upside versus a price of A$0.0330 (fairly valued). Cautious scenario A$0.0305, optimistic scenario A$0.0356. The calculation is refreshed regularly with new filings.
What is the revenue of Imugene Ltd (IMU)?
Imugene Ltd reported trailing-twelve-month revenue of about A$2.1M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Imugene Ltd (IMU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Imugene Ltd it is A$0.0330 per share (as of Nov 17, 2026), against a price of A$0.0330.
Is Imugene Ltd stock overvalued or undervalued in 2026?
As of Nov 17, 2026, IMU trades below its calculated fair value: price A$0.0330, fair value A$0.0330, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IMU?
No. The price is what the market pays today (A$0.0330); the fair value is what the company's own numbers justify (A$0.0330). For Imugene Ltd the two are A$0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Imugene Ltd worth?
The market values Imugene Ltd at about A$18.3M (market capitalisation, as of Nov 17, 2026). Per share that is A$0.0330; our models calculate a fair value of A$0.0330 per share.
What do the bullish and bearish scenarios say about IMU?
Our models span a range for Imugene Ltd: cautious scenario A$0.0305, base A$0.0330, optimistic A$0.0356 per share (as of Nov 17, 2026, price A$0.0330). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of IMU?
The PEG ratio of Imugene Ltd is 4.07 (P/E divided by earnings growth, as of Nov 17, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Imugene Ltd (IMU)?
Balance-sheet figures for Imugene Ltd (as of Nov 17, 2026): return on equity −314.0%, debt of 0.29 per unit of equity. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is IMU from its 52-week high?
Imugene Ltd trades at A$0.0330, about 92% below its 52-week high of A$0.3900 and 10% above the low of A$0.0300 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0330 is for.
Which stocks are comparable to Imugene Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Imugene Ltd stock attractive at the current price?
The data as of Nov 17, 2026: price A$0.0330, calculated fair value A$0.0330 (+0%), Quality Score 21/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Imugene Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Imugene Ltd (IMU)?
The closing price on Nov 17, 2026 was A$0.0330. Our estimate is A$0.0330, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Imugene Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Imugene Ltd

How large is the market capitalisation of Imugene Ltd (IMU)?
The market capitalisation of Imugene Ltd is A$18.3M (≈ $12.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Imugene Ltd (IMU)?
The price-to-sales ratio of Imugene Ltd is 10.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Imugene Ltd (IMU)?
Earnings per share at Imugene Ltd are A$−0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Imugene Ltd (IMU)?
The return on equity (ROE) of Imugene Ltd is −314% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Imugene Ltd (IMU)?
On an EBIT basis the return on assets of Imugene Ltd is −113% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Imugene Ltd (IMU)?
The operating margin of Imugene Ltd is −5,246% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Imugene Ltd (IMU)?
Revenue at Imugene Ltd is down 59.8% versus a year earlier (3y avg −30.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Imugene Ltd (IMU) generate?
The free cash flow of Imugene Ltd is −A$44.9M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Imugene Ltd (IMU) carry?
The net debt of Imugene Ltd is A$3.7M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Imugene Ltd in the live analysis

One click puts Imugene Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.